ES2618353T3 - Clasificación de tumores y pronóstico del cáncer de mama - Google Patents
Clasificación de tumores y pronóstico del cáncer de mama Download PDFInfo
- Publication number
- ES2618353T3 ES2618353T3 ES08872935T ES08872935T ES2618353T3 ES 2618353 T3 ES2618353 T3 ES 2618353T3 ES 08872935 T ES08872935 T ES 08872935T ES 08872935 T ES08872935 T ES 08872935T ES 2618353 T3 ES2618353 T3 ES 2618353T3
- Authority
- ES
- Spain
- Prior art keywords
- ratio
- subject
- index
- classified
- cut
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Un método que comprende: analizar una muestra de células de cáncer de mama de un sujeto que padece cáncer de mama para determinar el nivel de expresión de Bub1B, CENPA, NEK2, RACGAP1 y RRM2 y sumar los niveles de expresión como un único índice para determinar un único índice para el sujeto; analizar el ratio de la expresión de HoxB13 frente a la expresión IL17BR (ratio H:I) para el sujeto en la muestra; comparar el índice del sujeto con un punto de corte del índice; comparar el ratio H:I del sujeto con un punto de corte del ratio H:I; en el que el punto de corte del índice y el punto de corte del ratio H:I se determinan como los puntos de corte naturales en una distribución bimodal de índices o ratios H:I en un conjunto de datos, en el que el conjunto de datos comprende índices o ratios H:I de pacientes que (i) tuvieron reaparición del cáncer y (ii) no tuvieron reaparición del cáncer; clasificar el índice o el ratio H:I del sujeto como de "alto riesgo" si el índice o el ratio H:I corresponde a un valor por encima del punto de corte del índice o del punto de corte del ratio H:I o clasificar el índice o el ratio H:I del paciente como de "bajo riesgo" si el índice o el valor de H:I corresponde a un valor igual o inferior al valor de punto de corte del índice o el valor de punto de corte del ratio H:I, y determinar que el sujeto tiene un riesgo aumentado de reaparición del cáncer si el índice y el ratio H:I del sujeto se clasifican como de alto riesgo, o predecir que el sujeto tiene un riesgo reducido de reaparición del cáncer si el índice y el ratio H:I del sujeto se clasifican como de bajo riesgo o si el índice del sujeto se clasifica como de bajo riesgo y el ratio H:I del sujeto se clasifica como de alto riesgo, o predecir que el sujeto tiene una probabilidad intermedia de reaparición del cáncer si el índice del sujeto se clasifica como de alto riesgo y el ratio H:I del sujeto se clasifica como de bajo riesgo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97052907P | 2007-09-06 | 2007-09-06 | |
| PCT/US2008/075528 WO2009108215A1 (en) | 2007-09-06 | 2008-09-06 | Tumor grading and cancer prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2618353T3 true ES2618353T3 (es) | 2017-06-21 |
Family
ID=40790735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08872935T Active ES2618353T3 (es) | 2007-09-06 | 2008-09-06 | Clasificación de tumores y pronóstico del cáncer de mama |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9447470B2 (es) |
| EP (1) | EP2195467B1 (es) |
| JP (2) | JP2010538609A (es) |
| CN (1) | CN102395682B (es) |
| CA (1) | CA2698569A1 (es) |
| ES (1) | ES2618353T3 (es) |
| WO (1) | WO2009108215A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
| US9856533B2 (en) | 2003-09-19 | 2018-01-02 | Biotheranostics, Inc. | Predicting breast cancer treatment outcome |
| DK1899484T3 (da) * | 2005-06-03 | 2015-11-23 | Biotheranostics Inc | Identifikation af tumorer og væv |
| WO2010151731A1 (en) * | 2009-06-26 | 2010-12-29 | University Of Utah Research Foundation | Materials and methods for the identification of drug-resistant cancers and treatment of same |
| WO2012079059A2 (en) | 2010-12-09 | 2012-06-14 | Biotheranostics, Inc. | Post-treatment breast cancer prognosis |
| US20120269418A1 (en) * | 2011-04-22 | 2012-10-25 | Ge Global Research | Analyzing the expression of biomarkers in cells with clusters |
| US9470693B2 (en) | 2012-05-18 | 2016-10-18 | University Of North Dakota | Method for quantifying proteins and isoforms thereof |
| CN104704128A (zh) * | 2012-05-22 | 2015-06-10 | 纳米线科技公司 | 预测乳腺癌结果的nano46基因和方法 |
| WO2013190081A1 (en) * | 2012-06-22 | 2013-12-27 | Proyecto De Biomedicina Cima, S.L. | Methods and reagents for the prognosis of cancer |
| US20150072021A1 (en) * | 2013-09-09 | 2015-03-12 | British Columbia Cancer Agency Branch | Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy |
| EP3044335B1 (en) | 2013-09-11 | 2020-09-09 | Bio Theranostics, Inc. | Predicting breast cancer recurrence |
| US10253369B2 (en) | 2014-05-29 | 2019-04-09 | Biotheranostics, Inc. | Predicting likelihood of response to combination therapy |
| EP3374526A4 (en) | 2015-11-13 | 2019-09-11 | Biotheranostics, Inc. | INTEGRATION OF TUMOR CHARACTERISTICS WITH A BREAST CANINE INDEX |
| CN107119055A (zh) * | 2017-05-18 | 2017-09-01 | 南京中医药大学 | 分子标志物bub1b基因及其应用 |
| CN110021433B (zh) * | 2017-08-30 | 2023-11-17 | 中山大学 | 一种用于精准预测胃肠胰神经内分泌肿瘤患者预后的系统 |
| EP3837548A2 (en) * | 2018-08-17 | 2021-06-23 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for the treatment of breast cancer |
| CN109706160A (zh) * | 2019-02-22 | 2019-05-03 | 广西医科大学 | 重组人蛋白激酶Nek2蛋白表达和纯化方法 |
| KR102405973B1 (ko) * | 2019-09-20 | 2022-06-07 | 고려대학교 산학협력단 | 유방암 초음파 영상과 유전자 정보를 이용한 유방암 치료법 선택을 위한 정보를 제공하는 방법 |
| KR102508210B1 (ko) * | 2020-10-16 | 2023-03-10 | 고려대학교 산학협력단 | 유방암 초음파 영상을 이용한 dna 유전자 정보를 제공하는 방법 |
| CN115029437A (zh) * | 2022-04-28 | 2022-09-09 | 深圳市陆为生物技术有限公司 | 检测样本中生物标志物的试剂在制备乳腺癌患者化疗响应评估产品中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
| WO2000029044A2 (en) | 1998-11-13 | 2000-05-25 | Pro Duct Health, Inc. | Devices and methods to identify ductal orifices during nipple aspiration |
| US20030228575A1 (en) * | 2001-01-31 | 2003-12-11 | Yuk Ming Dennis Lo | Combination of circulating epstein-barr virus (EBV) DNA in the serum or plasma of patients and a method to assess EBV subtypes for the prediction and detection of epstein-barr virus associated cancers |
| CA2443627A1 (en) * | 2001-05-16 | 2002-11-21 | Novartis Ag | Genes expressed in breast cancer as prognostic and therapeutic targets |
| US20030138793A1 (en) * | 2001-06-10 | 2003-07-24 | Irm Llc, A Delaware Limited Liability Company | Molecular signatures of commonly fatal carcinomas |
| US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
| DK1641810T4 (en) * | 2003-06-24 | 2017-07-03 | Genomic Health Inc | Predicting the likelihood of cancer recurrence |
| ES2651849T3 (es) * | 2003-07-10 | 2018-01-30 | Genomic Health, Inc. | Algoritmo del perfil de expresión y test para el pronóstico del cáncer |
| BRPI0414446A (pt) * | 2003-09-18 | 2006-11-14 | Genmab As | métodos para triar um agente terapêutico, para a supressão da sequência de polinucleotìdeo, para o tratamento de um cáncer não dependente de esteróide, para triar a ligação de um agente especificamente a um polinucleotìdeo e para determinar se um paciente está em risco de desenvolver ou ter um cáncer não dependente de esteróide, composição farmacêutica, usos de um agente terapêutico, de uma molécula anti-sentido ou de uma célula que expressa e/ou contém a molécula anti-sentido, de pelo menos uma das proteìnas de membrana imunogênicas, fragmentos, derivados ou homólogos destas ou de uma célula que contém e/ou que expressa pelo menos uma das proteìnas de membranas imunogênicas ou fragmentos, derivados ou homólogos destas e de um agente ou anticorpo, agente, e, kit para identificar um paciente em risco de desenvolver ou ter cáncer não dependente de esteróide |
| BRPI0414553A (pt) | 2003-09-19 | 2006-11-07 | Arcturus Bioscience Inc | previsão do resultado de tratamento contra o cáncer de mama |
| US9856533B2 (en) | 2003-09-19 | 2018-01-02 | Biotheranostics, Inc. | Predicting breast cancer treatment outcome |
| US7504214B2 (en) | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
| US7498693B2 (en) | 2004-02-18 | 2009-03-03 | Diversified Technologies, Inc. | More compact and higher reliability power source system |
| AU2006246241A1 (en) * | 2005-05-13 | 2006-11-16 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
| DK1899484T3 (da) * | 2005-06-03 | 2015-11-23 | Biotheranostics Inc | Identifikation af tumorer og væv |
-
2008
- 2008-09-06 CA CA2698569A patent/CA2698569A1/en not_active Abandoned
- 2008-09-06 JP JP2010524215A patent/JP2010538609A/ja active Pending
- 2008-09-06 EP EP08872935.5A patent/EP2195467B1/en active Active
- 2008-09-06 ES ES08872935T patent/ES2618353T3/es active Active
- 2008-09-06 CN CN200880114588.6A patent/CN102395682B/zh active Active
- 2008-09-06 WO PCT/US2008/075528 patent/WO2009108215A1/en active Application Filing
-
2010
- 2010-03-06 US US12/718,973 patent/US9447470B2/en active Active
-
2014
- 2014-09-16 JP JP2014187715A patent/JP2015057055A/ja active Pending
-
2017
- 2017-11-08 US US15/807,456 patent/US11021754B2/en active Active
-
2021
- 2021-04-23 US US17/239,207 patent/US20210371934A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2195467B1 (en) | 2016-12-14 |
| US11021754B2 (en) | 2021-06-01 |
| US9447470B2 (en) | 2016-09-20 |
| CN102395682A (zh) | 2012-03-28 |
| JP2015057055A (ja) | 2015-03-26 |
| US20210371934A1 (en) | 2021-12-02 |
| US20180291461A1 (en) | 2018-10-11 |
| CN102395682B (zh) | 2015-09-30 |
| JP2010538609A (ja) | 2010-12-16 |
| EP2195467A1 (en) | 2010-06-16 |
| WO2009108215A1 (en) | 2009-09-03 |
| US20110136680A1 (en) | 2011-06-09 |
| CA2698569A1 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2618353T3 (es) | Clasificación de tumores y pronóstico del cáncer de mama | |
| Miyamoto et al. | Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post–World Health Organization/International Society of Urological Pathology classification cohort from a single academic center | |
| Budczies et al. | Classical pathology and mutational load of breast cancer–integration of two worlds | |
| Gusterson | Do'basal-like'breast cancers really exist? | |
| Manatakis et al. | Association of baseline neutrophil-to-lymphocyte ratio with clinicopathological characteristics of papillary thyroid carcinoma | |
| Passoni et al. | Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis | |
| Ebrahimi et al. | The prognosis of N2b and N2c lymph node disease in oral squamous cell carcinoma is determined by the number of metastatic lymph nodes rather than laterality: evidence to support a revision of the American Joint Committee on Cancer staging system | |
| NZ578283A (en) | Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring | |
| NZ705645A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| Huang et al. | Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer | |
| EP2558865A4 (en) | METHOD AND KIT FOR CANCER DIAGNOSIS | |
| Granit et al. | Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition | |
| Qi et al. | Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis | |
| MY193895A (en) | Combination test for colorectal cancer | |
| Ball et al. | Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer | |
| Xie et al. | Construction of m6A-related lncRNA prognostic signature model and immunomodulatory effect in glioblastoma multiforme | |
| Wu et al. | Expressions of m6A RNA methylation regulators and their clinical predictive value in cervical squamous cell carcinoma and endometrial adenocarcinoma | |
| Zhang et al. | Identification of a recurrence signature and validation of cell infiltration level of thyroid cancer microenvironment | |
| Gao et al. | Impact of examined lymph node count and lymph node density on overall survival of penile cancer | |
| Kaabipour et al. | p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study | |
| MY195697A (en) | Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof | |
| Ha et al. | Differential expression of forkhead box M1 and its downstream cyclin‐dependent kinase inhibitors p27kip1 and p21waf1/cip1 in the diagnosis of pulmonary neuroendocrine tumours | |
| Lu et al. | A novel prognostic model for oral squamous cell carcinoma: The functions and prognostic values of RNA-binding proteins | |
| Xu et al. | Risk prediction of second primary malignancies in primary early-stage ovarian Cancer survivors: a SEER-Based National Population-Based Cohort Study | |
| Zhuang et al. | Prognostic stratification based on a novel nomogram for solitary large hepatocellular carcinoma after curative resection |